Kura Oncology (KURA) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.77

Estimate

-$0.88

Surprise

+12.1%

Revenue (period 2026-06-30)

$20.9M

Score today

5.9/10

Revenue source: xbrl.

Kura Oncology (KURA) reported a narrower loss than forecast — diluted EPS of -$0.77 against the -$0.88 estimate (a 12.1% beat on a still-unprofitable quarter).

• Accelerant Holdings, CorMedix, Birkenstock And Other Big Stocks Moving Higher On Thursday — benzinga, 2026-08-13
• Wedbush Maintains Outperform on Kura Oncology, Raises Price Target to $38 — benzinga, 2026-08-13
• Kura Oncology Q2 EPS $(0.77) Beats $(0.87) Estimate, Sales $20.874M Miss $21.420M Estimate — benzinga, 2026-08-12

TrendMatrix currently rates KURA Sell at 5.9/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's +12.1% surprise compares with a -51.3% four-quarter average. Next scheduled report: 2026-11-03.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$11.90

Price target

$27.84

Stop

$11.06

Upside to target

+133.9%

Reward-to-risk

8.9:1

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.06B

P/E (fwd)

-5.2

52-week range

$7.36–$12.90

Off 52-week high

7.8%

RSI (14)

78

Volume vs avg

1.10×

Score today

5.9/10